Schnekenburger, Michael; Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Luxembourg, Luxembourg
Lorant, Anne; Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Luxembourg, Luxembourg
Gajulapalli, Sruthi Reddy; Research Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, Republic of Korea
Rajora, Ridhika; Research Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, Republic of Korea
Lee, Jin-Young; Research Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, Republic of Korea
Mazumder, Aloran; Research Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, Republic of Korea
Yang, Haeun; Research Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, Republic of Korea
Christov, Christo; Faculté de Médecine, Université de Lorraine, Vandœuvre-lès-Nancy, France
Kang, Hyoung Jin; Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul National University Children's Hospital, Seoul, Republic of Korea
Pirotte, Bernard ; Université de Liège - ULiège > Département de pharmacie
Diederich, Marc ; Research Institute of Pharmaceutical Sciences & Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, Republic of Korea
Language :
English
Title :
Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia as an immunogenic anticancer strategy.
Seoul National University National Research Foundation of Korea
Funding text :
LBMCC: \u201CRecherche Cancer et Sang\u201D foundation, the \u201CRecherches Scientifiques Luxembourg\u201D, the \u201CEen H\u00E4erz fir kriibskrank Kanner\u201D, the Action LIONS \u201CVaincre le Cancer\u201D and T\u00E9l\u00E9vie Luxembourg. SNU: National Research Foundation (NRF) (Grant Number 370C\u201020220063); MEST of Korea for Tumor Microenvironment Global Core Research Center (GCRC) (Grant Number 2011\u20100030001); Brain Korea (BK21) PLUS program and Creative\u2010Pioneering Researchers Program at Seoul National University (Funding number: 370C\u201020160062). Sruthi Reddy Gajulapalli and Ridhika Rajora were supported by grants for the \u201CGraduate Scholarship for Excellent Foreign Students\u201D program.
Koschmieder S, Vetrie D. Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options. Semin Cancer Biol. 2018;51:180–197.
Wu QJ, Zhang TN, Chen HH, Yu XF, Lv JL, Liu YY, et al. The sirtuin family in health and disease. Signal Transduct Target Ther. 2022;7(1):402.
Carafa V, Altucci L, Nebbioso A. Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype. Front Pharmacol. 2019;10:38.
Chen G, Huang P, Hu C. The role of SIRT2 in cancer: A novel therapeutic target. Int J Cancer. 2020;147(12):3297–3304.
Schnekenburger M, Goffin E, Lee JY, Jang JY, Mazumder A, Ji S, et al. Discovery and Characterization of R/S-N-3-Cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1- benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines. J Med Chem. 2017;60(11):4714–4733.
de Beauchamp L, Himonas E, Helgason GV. Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia. 2022;36(1):1–12.
Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2022;22(1):45–64.
Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487–500.
Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11(11):1013.
